Close Menu

NEW YORK (GenomeWeb) – Investment bank Jefferies today initiated coverage of the stock of transplant diagnostics firm CareDx with a Buy rating and a price target of $35.

In a note to investors, Jefferies analyst Brandon Couillard said that the company is well positioned as a leader in the transplant diagnostics market — which he estimated at more than $2 billion — with two tests on the market that serve an unmet need for non-invasive detection of heart and kidney post-transplant rejection.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.